39.94
price up icon1.09%   0.43
after-market Handel nachbörslich: 39.94
loading
Schlusskurs vom Vortag:
$39.51
Offen:
$40.251
24-Stunden-Volumen:
3.31M
Relative Volume:
2.05
Marktkapitalisierung:
$5.86B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-13.14
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+0.76%
1M Leistung:
+19.19%
6M Leistung:
+14.24%
1J Leistung:
-15.22%
1-Tages-Spanne:
Value
$39.72
$40.82
1-Wochen-Bereich:
Value
$38.98
$40.82
52-Wochen-Spanne:
Value
$23.95
$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
Firmenname
Ionis Pharmaceuticals Inc
Name
Telefon
(760) 931-9200
Name
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Name
Mitarbeiter
927
Name
Twitter
@ionispharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
IONS's Discussions on Twitter

Vergleichen Sie IONS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
39.94 5.86B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-07 Eingeleitet H.C. Wainwright Buy
2025-03-31 Eingeleitet Redburn Atlantic Neutral
2024-08-02 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-07-24 Hochstufung Leerink Partners Market Perform → Outperform
2024-07-16 Fortgesetzt Jefferies Buy
2024-06-14 Hochstufung Bernstein Underperform → Mkt Perform
2024-04-10 Hochstufung Wolfe Research Peer Perform → Outperform
2024-01-02 Hochstufung BofA Securities Neutral → Buy
2023-10-23 Hochstufung BofA Securities Underperform → Neutral
2023-09-29 Eingeleitet Raymond James Strong Buy
2023-07-31 Hochstufung Citigroup Neutral → Buy
2023-06-07 Fortgesetzt Piper Sandler Overweight
2023-05-04 Hochstufung Citigroup Sell → Neutral
2023-03-21 Eingeleitet Bernstein Underperform
2022-12-21 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-09-09 Fortgesetzt Morgan Stanley Overweight
2022-07-18 Fortgesetzt Oppenheimer Outperform
2022-03-31 Fortgesetzt Piper Sandler Overweight
2022-03-01 Eingeleitet Citigroup Sell
2022-03-01 Eingeleitet Guggenheim Buy
2022-02-01 Herabstufung BofA Securities Buy → Underperform
2021-12-14 Hochstufung William Blair Mkt Perform → Outperform
2021-05-07 Hochstufung UBS Sell → Neutral
2021-03-01 Hochstufung Barclays Underweight → Equal Weight
2020-12-16 Eingeleitet UBS Sell
2020-12-15 Hochstufung Cowen Market Perform → Outperform
2020-09-14 Fortgesetzt JP Morgan Neutral
2020-09-02 Eingeleitet The Benchmark Company Hold
2020-06-01 Fortgesetzt Oppenheimer Outperform
2020-05-13 Eingeleitet RBC Capital Mkts Outperform
2020-03-05 Eingeleitet Citigroup Buy
2019-12-13 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-11-07 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-09-10 Hochstufung Bernstein Mkt Perform → Outperform
2018-08-08 Bestätigt Stifel Hold
2018-08-07 Bestätigt Stifel Hold
2018-05-08 Herabstufung Evercore ISI Outperform → In-line
2017-10-06 Fortgesetzt Goldman Sell
2017-08-17 Eingeleitet Evercore ISI Outperform
2017-08-09 Bestätigt Stifel Hold
2017-03-10 Herabstufung Goldman Neutral → Sell
2016-12-28 Bestätigt BMO Capital Markets Outperform
2016-12-27 Bestätigt Leerink Partners Mkt Perform
Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

pulisher
Jun 17, 2025

Global RNAi Technology Market: Opportunities in Targeted - openPR.com

Jun 17, 2025
pulisher
Jun 16, 2025

Antisense Oligonucleotides Market is expected to reach US$ - openPR.com

Jun 16, 2025
pulisher
Jun 13, 2025

Ionis announces leadership change as chief development officer plans retirement - Investing.com India

Jun 13, 2025
pulisher
Jun 12, 2025

Ionis announces Dr. Richard Geary, chief development officer, to - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis announces leadership change as chief development officer plans retirement By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

JP Morgan Maintains Neutral Rating, Raises Price Target for Ionis Pharmaceuticals (IONS) | IONS Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Analyst Expectations For Ionis Pharmaceuticals's Future - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis Pharmaceuticals (IONS) Announces Leadership Change in Development | IONS Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 | IONS Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis Pharmaceuticals Announces Dr Richard Geary, Chief Development Officer, To Retire - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 - The Joplin Globe

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits - Quantisnow

Jun 12, 2025
pulisher
Jun 12, 2025

JPMorgan Adjusts Ionis Pharmaceuticals (IONS) Price Target to $4 - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

JPMorgan Adjusts Ionis Pharmaceuticals (IONS) Price Target to $48 | IONS Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Ionis doses first subject in Phase III trial of Angelman syndrome therapy - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome | IONS Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ionis begins phase 3 trial of Angelman syndrome treatment By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Ionis Pharmaceuticals (IONS) Advances with Phase 3 REVEAL Study for Angelman Syndrome | IONS Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Ionis Pharmaceuticals reports annual meeting results - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Ionis Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

Ionis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Day 8 of Gains Streak for Ionis Pharmaceuticals Stock with 13% Return (vs. 5.1% YTD) [6/9/2025] - Trefis

Jun 10, 2025
pulisher
Jun 09, 2025

Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com

Jun 09, 2025
pulisher
Jun 07, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) versus Akero Therapeutics (NASDAQ:AKRO) Financial Contrast - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Transcript : Ionis Pharmaceuticals, Inc.Shareholder/Analyst Call - marketscreener.com

Jun 05, 2025
pulisher
Jun 01, 2025

10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 31, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

May 31, 2025
pulisher
May 30, 2025

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research ReportPfizer, Ionis Pharmaceuticals - openPR.com

May 29, 2025
pulisher
May 28, 2025

Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com

May 28, 2025
pulisher
May 27, 2025

Ionis Pharmaceuticals’ SWOT analysis: RNA therapeutics firm faces pivotal year for stock - Investing.com

May 27, 2025
pulisher
May 26, 2025

Angioedema Treatment Market Insights and Forecast from 2025 - openPR.com

May 26, 2025
pulisher
May 26, 2025

Hereditary Angioedema Drugs Market 2034: EMA, PDMA, FDA - openPR.com

May 26, 2025
pulisher
May 25, 2025

D. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

May 25, 2025
pulisher
May 23, 2025

Ionis’ olezarsen shows new promise with strong Phase III results - The Pharma Letter

May 23, 2025
pulisher
May 23, 2025

December 2027 Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq

May 23, 2025
pulisher
May 22, 2025

Ionis reports success in olezarsen trial for high triglycerides - Yahoo

May 22, 2025
pulisher
May 22, 2025

Treatment-Resistant Hypertension Market: Epidemiology, - openPR.com

May 22, 2025
pulisher
May 22, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Earns Buy Rating from HC Wainwright - Defense World

May 22, 2025
pulisher
May 21, 2025

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN

May 21, 2025
pulisher
May 21, 2025

Hereditary Angioedema Market Set to Grow Substantially Through - openPR.com

May 21, 2025
pulisher
May 21, 2025

Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08 - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Janus Henderson Group PLC - Defense World

May 21, 2025
pulisher
May 20, 2025

Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena

May 20, 2025

Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Birchler Brian
EVP, Corp and Development Ops
Apr 15 '25
Option Exercise
0.00
1,875
0
57,340
Birchler Brian
EVP, Corp and Development Ops
Apr 16 '25
Sale
28.37
680
19,292
56,660
Jenne Kyle
EVP, Chf GL Pdt Str Ofcr
Apr 15 '25
Option Exercise
0.00
12,226
0
14,215
Jenne Kyle
EVP, Chf GL Pdt Str Ofcr
Apr 16 '25
Sale
28.36
3,016
85,534
11,199
Baroldi Joseph
EVP, Chief Business Officer
Apr 15 '25
Option Exercise
0.00
10,837
0
35,854
Baroldi Joseph
EVP, Chief Business Officer
Apr 16 '25
Sale
28.40
3,928
111,555
31,926
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):